Mon Nov 24 23:15:00 UTC 2025: Okay, here’s a summary and a news article based on the provided text:

Summary:

Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS), Bhubaneswar have developed a novel TB vaccine, the HSP Subunit Vaccine in Adjuvant, designed to be more effective than the current BCG vaccine. The National Research Development Corporation (NRDC) facilitated a licensing agreement with TechInvention Lifecare Limited for the vaccine’s technology transfer and future commercialization. The vaccine addresses the unmet need for a more effective TB vaccine for adolescents and adults, given the current BCG vaccine’s limitations. This collaboration signifies a significant step in India’s fight against tuberculosis.

News Article:

New TB Vaccine to Combat Deadly Disease Set for Commercialization

Bhubaneswar, November 25, 2025 – A new vaccine offering enhanced protection against tuberculosis (TB) is poised to become commercially available, marking a significant advancement in the global fight against the deadly disease.

The HSP Subunit Vaccine in Adjuvant, developed collaboratively by the Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS), Bhubaneswar, aims to overcome the limitations of the current BCG vaccine, which offers limited protection against pulmonary TB in adolescents and adults.

Tuberculosis remains a major global health threat, claiming 1.23 million lives in 2024 alone, according to the World Health Organization (WHO). The new vaccine is designed to trigger a strong immune response, providing greater protection than the century-old BCG vaccine.

A quadripartite license agreement (QLA) between IIT Bhubaneswar, ILS, the National Research Development Corporation (NRDC), and TechInvention Lifecare Limited was signed, paving the way for technology transfer and commercialization of the novel vaccine. The NRDC played a crucial role in identifying and evaluating the technology, facilitating its advancement.

“This collaboration reflects the robustness of India’s research ecosystem and its commitment to addressing critical public health challenges,” stated a joint release from the institutions involved. TechInvention Lifecare Limited is committed to translating this indigenous vaccine technology into a viable public health solution.

The development and commercialization of the HSP Subunit Vaccine represent a significant step towards the United Nations Sustainable Development Goal of ending the TB epidemic by 2030.

Read More